Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug
|
Gilead stock toppled Thursday on a report CVS won't add
the company's new HIV prevention drug, Yeztugo, to its commercial
plans for now. |
Russia's War Against Ukraine Has Seen an Explosion in HIV Rates
Russia's HIV statistics and dynamics were far from encouraging long before the full-scale invasion of Ukraine. View article...